Thomas F. Lüscher/LinkedIn
Aug 5, 2026, 14:25
Thomas F. Lüscher: ZEUS Trial Highlights the Challenge of Translating Anti-Inflammatory Effects into Clinical Benefit
Thomas F. Lüscher, Director of Research, Education and Development and Consultant of Cardiology at Royal Brompton and Harefield Hospitals, shared a post on LinkedIn:
“ZEUS has been angry: Ziltivekimab reduced IL-6 and hsCRP, but did not translate into MACE risk reduction versus placebo in patients with ASCVD, CKD and inflammation (HR 0.99; CI 0.88-1.11) – will Artemis (AMI) and Hermes (HfpEF) be in better mood?
It is important to continue with these trials as CKD patients may be different, too late in the course of CVD to make a difference with IL-6 blockade.”
Stay updated with Hemostasis Today.
-
Aug 5, 2026, 20:30Denis Oduor: Patient Blood Management and Systemic Transfusion Reform
-
Aug 5, 2026, 20:15Salih Ehsan: Diagnostic Screening Strategy for Hemoglobinopathy Traits
-
Aug 5, 2026, 19:39Platelet-Derived Extracellular Vesicles for Hemostasis and Bleeding Reduction in TBI – Every Labs
-
Aug 5, 2026, 19:05Alfonso J. Tafur: Thromboinflammation and Hemostatic Dysfunction as Predictors of Early Pulmonary Embolism Mortality
-
Aug 5, 2026, 19:00Grigoris Gerotziafas: DU T2H 2026–2027 Enrolment Is Now Open
-
Aug 5, 2026, 19:00Konstantin Stark: Now Recruiting for the DFG Collaborative Research Center 1784
-
Aug 5, 2026, 18:59Should Genotype Guide Thromboprophylaxis in Pregnant Women With Antithrombin Deficiency? – RPTH Journal
-
Aug 5, 2026, 18:59Ayisha Munavar: Understanding PNH – A Rare Disease That Demands Early Recognition
-
Aug 5, 2026, 18:58Kalyan Roy: The Oxygen Delivery Paradox in Polycythaemia Vera